These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 10346683)

  • 1. The new Restatement (Third) of Torts--shelter from the product liability storm for pharmaceutical companies and medical device manufacturers?
    Wagner MJ; Peterson LL
    Food Drug Law J; 1998; 53(2):225-42. PubMed ID: 10346683
    [No Abstract]   [Full Text] [Related]  

  • 2. Section 8(c) of the proposed Restatement (Third) of Torts: is it really what the doctor ordered?
    Winchester JD
    Cornell Law Rev; 1997 Mar; 82(3):644-93. PubMed ID: 10343053
    [No Abstract]   [Full Text] [Related]  

  • 3. Permitting product liability litigation for FDA-approved drugs and devices promotes patient safety.
    Kesselheim AS
    Clin Pharmacol Ther; 2010 Jun; 87(6):645-7. PubMed ID: 20485322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manufacturers' liability for drugs and medical devices under the Restatement (Third) of Torts: Products Liability.
    Dreier WA
    Seton Hall Law Rev; 1999; 30(1):258-64. PubMed ID: 10848105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions.
    Chodock R; Yolkut D; Connolly DR
    Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. US bill to shield drug companies from product liability.
    Lenzer J
    BMJ; 2005 Jan; 330(7482):62. PubMed ID: 15637367
    [No Abstract]   [Full Text] [Related]  

  • 7. Tort claims and federal regulation of medical devices vs pharmaceuticals.
    Green M
    JAMA; 2009 Sep; 302(11):1169; author reply 1169-70. PubMed ID: 19755694
    [No Abstract]   [Full Text] [Related]  

  • 8. Defending an emerging threat: consumer fraud class action suits in pharmaceutical and medical device products-based litigation.
    Leghorn JJ; Allen C; Brewington T
    Food Drug Law J; 2006; 61(3):519-38. PubMed ID: 16989037
    [No Abstract]   [Full Text] [Related]  

  • 9. The Medical Device Safety Act of 2009.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2009 Apr; 360(15):1550-1. PubMed ID: 19297562
    [No Abstract]   [Full Text] [Related]  

  • 10. The Canadian perspective: trends in drug and medical device class actions in Canada.
    Vernon W
    Food Drug Law J; 2006; 61(3):569-76. PubMed ID: 16989040
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent developments in pharmaceutical products liability law: failure to warn, the learned intermediary defense, and other issues in the new millennium.
    Garbutt BJ; Hofmann ME
    Food Drug Law J; 2003; 58(2):269-86. PubMed ID: 12866558
    [No Abstract]   [Full Text] [Related]  

  • 12. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 13. Medical-legal analysis and considerations in product liability cases involving pharmaceutical companies.
    Woodside FC; Grunes AP; Comodeca JA
    Leg Med; 1989; ():125-43. PubMed ID: 2700004
    [No Abstract]   [Full Text] [Related]  

  • 14. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceutical industry wins "round one" in protections against product liability claims.
    Gatty B
    Hosp Formul; 1995 Apr; 30(4):238, 237. PubMed ID: 10141868
    [No Abstract]   [Full Text] [Related]  

  • 16. Reimagining the learned intermediary rule for the new pharmaceutical marketplace.
    Hall TS
    Seton Hall Law Rev; 2004; 35(1):193-261. PubMed ID: 15614980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The errors of error testing: potential liability issues for medication error testing of pharmaceutical trademarks under U.S. law.
    Thomas JA
    Food Drug Law J; 2004; 59(2):325-37. PubMed ID: 15298014
    [No Abstract]   [Full Text] [Related]  

  • 18. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global medicine does not make for global courts.
    Herling DJ; Brenner LM
    Food Drug Law J; 2005; 60(3):453-7. PubMed ID: 16304750
    [No Abstract]   [Full Text] [Related]  

  • 20. Direct-to-consumer advertising and shared liability for pharmaceutical manufacturers.
    Mello MM; Rosenthal M; Neumann PJ
    JAMA; 2003 Jan 22-29; 289(4):477-81. PubMed ID: 12533128
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.